Isogenic panel of clinically relevant cancer mutation cell lines! Using our expertise garnered as a leading CRISPR service provider, ASC has engineered 250+ isogenic, CRISPR cell lines with cancer mutations based on the COSMIC database, for use as clinically relevant in vitro (cell line) models for cancer research, drug discovery and screening applications.
- 271 Isogenic cell lines with largest mutation panel in market
- 40+ clinically actionable genes in MAPK Pathway and more (Ex. EGFR, ALK,
- Isogenically paired wild-type and mutant cell lines
- Footprint-free genome editing using CRISPR/Cas9; no genomic scars
- Knockout and knock-in based on COSMIC database
- Mutation are: clonally homogeneous, genetically validated and 100% homozygous
CRISPR Cell Line with Deletion Mutation in EGFR Gene
Figure 1. An 18 bp deletion in exon 19 of EGFR, corresponding to COSMIC mutation 6255 (c.2239_2256del18), was engineered using CRISPR/Cas9 into the RKO cell line. The homozygous positive clone, above, was identified, expanded, and confirmed by Sanger sequencing.
CRISPR Cell Line with Point Mutation in KRAS Gene
Figure 2. A G>T mutation at codon 12 of KRAS exon 2 (c.35G>T), corresponding to COSMIC mutation 520, was engineered into the RKO cell line. The homozygous positive clone, above, was identified, expanded, and confirmed by Sanger sequencing.
Isogenic cell lines are a unique toolset for studying cellular biology, such as the impact of genotype on cellular phenotype, as well as for parallel, high throughput screening to enable the discovery of therapeutic compounds that exhibit genotype-specific toxicity. Our comprehensive, mutation panel with 271 isogenic cell lines will serve an unmet need as pharmacogenomic reference standards and as precision tools for drug discovery and screening.
With clinically-relevant mutations in 40+ oncogenes, these cell lines have been engineered using CRISPR/Cas9, with precise mutations and without genomic scars (footprint-free):
- Isogenic, matched wild type control lines: well-characterized colorectal cancer cell lines (RKO and HCT116)
- Homozygous gene knockout, small fragment and SNP knock-in cell lines
- Genetically validated and clonally homogeneous cell lines
- Footprint-free CRISPR cell lines
Applications in cancer research
- Molecular and cellular mechanisms of cancer mutations
- Pharmacogenomic studies
- Drug target discovery and screening
- Preclinical development of personalized cancer treatment regimen